[Safety and effectiveness of biologics in treating inflammatory bowel diseases in pregnancy].
Inflammatory Bowel Diseases (IBD) affect mainly younger people. Biologic therapies are safe and effective in inducing and maintain remission in that patients. We reviewed herein the current knowledge about the safety and the effectiveness of biologic therapies in managing pregnant IBD patients.
Antonio
A
Tursi
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products / Q000009:adverse effects / Q000627:therapeutic use*; D000068582:Certolizumab Pegol; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D015212:Inflammatory Bowel Diseases / Q000628:therapy*; D000069285:Infliximab; D011092:Polyethylene Glycols / Q000627:therapeutic use; D011247:Pregnancy; D011248:Pregnancy Complications / Q000628:therapy*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D001688:Biological Products; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D000069285:Infliximab; D000068879:Adalimumab; D000068582:Certolizumab Pegol